We are very pleased to announce that the next ISPOR (NZ) webinar will be delivered by Dr Mike Paulden, on approaches to incorporating equity weights in health technology assessment processes.
Dr Paulden is an Assistant Professor at the School of Public Health, University of Alberta, Canada. He is a health economist with an interest in methods for the economic evaluation of health technologies.
The UK's National Institute for Health and Care Excellence (NICE) recently launched a consultation on the methods it uses to evaluate new health technologies, and has highlighted the issue of how 'modifiers', including equity weights, should be incorporated into its processes. In this webinar, Mike will discuss a recent study which demonstrated that NICE's current approach to equity weighting has the effect of reducing both population health and equity-weighted population health, a fundamental problem that appears to place NICE in contravention of its principles and obligations.
He will discuss potential methods for modifying NICE's current approach to address this problem, consider the merits of NICE abandoning its current approach to equity weighting and adopting a standard 'net benefit' approach in its place, and make recommendations as to how NICE can move forward with the use of 'modifiers', including equity weights, in its decision making.
These issues are very relevant to the problems faced in New Zealand by PHARMAC, which is currently reviewing its Prescription for Pharmacoeconomic Analysis describing how economic evaluations should be conducted and interpreted in its health technology assessment processes.
The webinar will be held at 11 a.m. on Thursday 18 March. To register, please complete the registration form here. Attendance is free for ISPOR (NZ) members, and $25 for non-members.
Comments